Últimas noticias sobre IO Biotech (NASDAQ:IOBT) Bolsa

IO Biotech

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

IO Biotech Inc

DA Davidson analyst Matt Summerville maintains Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) with a Buy and maintains $155 price target.

News

Price Target

Analyst Ratings

DA Davidson Maintains Buy on Modine Manufacturing, Maintains $155 Price Target

RBC Capital analyst Sabahat Khan reiterates Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) with a Sector Perform and maintains $54 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Polaris, Maintains $54 Price Target

WIIM

Coffee Holding shares are trading lower after the company announced a $30 million shelf offering.

RBC Capital analyst Mike Dahl reiterates Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) with a Outperform and maintains $212 price target.

RBC Capital Reiterates Outperform on Owens-Corning, Maintains $212 Price Target

DA Davidson analyst Linda Bolton Weiser maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Neutral and lowers the price target from $80 to $75.

DA Davidson Maintains Neutral on e.l.f. Beauty, Lowers Price Target to $75

If the cruise industry were a poker game, Norwegian Cruise Line Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) just pushed all its chips to the center of the table, while Royal Caribbean Cruises Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) is <a href="https://www.benzinga.com/topic/cruise-lines">calmly stacking its winnings</a>. 
JPMorgan analyst Matthew R. Boss has upgraded Norwegian Cruise Line stock to Overweight, citing resilience in consumer demand and a value gap that still gives cruises an edge over land-based vacations. 
Meanwhile, Royal Caribbean is playing from a position of strength, riding a wave of bullish momentum. 
So, which stock deserves a spot in your portfolio?
Read Also: <a href="https://www.benzinga.com//node/44263340">Turbulence Ahead: 3 ETFs Hit By Slump In Travel Stocks</a>
<h2 class="wp-block-heading">Norwegian Cruise Line: Ready To Ride The Recovery Wave?</h2>
After CFO Mark Kempa and investor relations chief Sarah Inmon dropped anchor at JPMorgan's Gaming, Lodging, Restaurant &amp; Leisure Conference, Boss saw enough to bump Norwegian Cruise Line's rating up from Neutral.
Management's key message? No turbulence in demand, no booking curve distortions, and no sign of onboard spending slowing down &#8211; even in high-discretionary categories like spas and casinos.
Kempa pointed out that cruises still offer a 30%-35% price advantage over land-based vacations, down from 40% a year ago but well above pre-pandemic levels. The "Experience Gap" is another key driver, as better ship amenities and private island exclusivity (hello, Great Stirrup Cay) keep customers hooked.
Norwegian Cruise Line's high-income clientele ($200K+ household income) and a still-underpenetrated cruise market (only 3-4% of global vacations) add further insulation against macroeconomic jitters.
Long term, Norwegian Cruise Line is looking at a major catalyst: a potential Russia-Ukraine truce. The Baltic region, a &#8220;gold mine&#8221; for the industry, could unlock a revenue surge by summer 2026, with Norwegian poised to capitalize on it more than competitors. Meanwhile, cost-saving initiatives exceeding $300M through 2026 should boost margins back to 2019 levels.
<h2 class="wp-block-heading">Royal Caribbean: Still The King Of The Ocean?</h2>
While Norwegian is gaining steam, Royal Caribbean isn't backing down. Coming off an "extremely bullish" Investor Day in March, Royal Caribbean continues to dominate with strong demand trends, efficient cost controls, and a premium customer experience. 
The stock is already cruising at high altitudes &#8211; trading above $200 with a price target of $298 &#8211; but the upside still looks compelling.
Boss acknowledges Royal Caribbean's superior execution but sees Norwegian Cruise Line as an underdog that's finally finding its stride. While Royal Caribbean's brand power and scale make it a juggernaut, Norwegian Cruise Line is sharpening its competitive edge with a high-end luxury push (Oceania &amp; Regent) and pricing optimizations. 
Both players are benefitting from cruise's broader industry tailwinds, but Norwegian has more room to prove itself.
Read Also: <a href="https://www.benzinga.com//node/44318426">Here&#8217;s How Much $1000 Invested In Royal Caribbean Gr 5 Years Ago Would Be Worth Today</a>
<h2 class="wp-block-heading">A Tale Of Two Strategies</h2>
Norwegian Cruise Line is the comeback story, playing from a position of strength with potential upside surprises in luxury and international markets. Royal Caribbean, already a leader, continues to execute flawlessly but may have less explosive growth left in the tank. JPMorgan sees Norwegian as the more compelling risk-reward bet at current levels, with a price target of $30.
The seas may be calm for now, but in this battle for dominance, expect plenty of waves ahead. Are you sailing with the market leader or betting on the underdog?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44355195/retail-sales-rebound-less-than-expected-in-february-online-healthcare-spending-show-strong-gains">Retail Sales Rebound Less Than Expected In February: Online, Healthcare Spending Show Strong Gains</a></li>
</ul>
Image via Shutterstock

Analyst Color

Entertainment

Long Ideas

Trading Ideas

General

NCLH

Cruise Wars: Norwegian Vs. Royal Caribbean – Who's Ruling The High Seas?

On Monday, PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) announced its plan to acquire the popular prebiotic soda brand, Poppi, in a <a href="https://www.benzinga.com/pressreleases/25/03/n44354698/pepsico-to-acquire-poppi" target="_blank" rel="noreferrer noopener">deal worth $1.95 billion.</a>
This includes $300 million in expected tax benefits, reducing the net purchase price to $1.65 billion. The acquisition also comes with an additional earnout consideration based on achieving specific performance goals after the transaction&#8217;s closure.
&#8220;More than ever, consumers are looking for convenient and great-tasting options that fit their lifestyles and respond to their growing interest in health and wellness. poppi is a great complement to our portfolio transformation efforts to meet these needs,&#8221; said Chairman and CEO Ramon Laguarta.
Poppi&#8217;s acquisition comes as the rapidly growing functional soda brand has achieved notable success thanks to its distinctive mix of prebiotics, fruit juice, and apple cider vinegar.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/03/44356299/why-is-clothing-firm-guess-stock-surging-today" rel="noreferrer noopener">Why Is Clothing Firm Guess Stock Surging Today?</a>
The product, renowned for its low calorie count and no more than five grams of sugar per serving, has built a dedicated and enthusiastic following.
Founded by Allison and Stephen Ellsworth, Poppi gained further visibility after being featured on Shark Tank, and secured backing from Rohan Oza and CAVU Consumer Partners, cementing its place as a leader in the beverage market.
&#8220;Allison and the poppi team have built a magnetic brand that&#8217;s ahead of the trends, with a loyal consumer base and a demonstrated capacity for growth. We are big fans of the poppi brand movement and believe this incredible brand paired with our commercial capabilities will drive continued growth and innovation for years to come,&#8221; said CEO, PepsiCo Beverages U.S., Ram Krishnan.
With the transaction now subject to regulatory approval and other standard conditions, the deal is expected to further expand PepsiCo&#8217;s presence in the functional beverage market.
The exact terms of the deal beyond the financial aspects have not been disclosed. PepsiCo held $8.5 billion in cash and equivalents as of December 28.
Price Action: PEP shares traded higher by 1.86% at $151.35 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44352234/astrazeneca-seals-deal-for-esobiotec-to-advance-cell-therapy-details" target="_blank" rel="noreferrer noopener">AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details</a></li>
</ul>
Photo via Shutterstock.

Equities

Large Cap

Movers

PepsiCo Bets Big On Prebiotic Sodas With $1.95 Billion Poppi Acquisition: Details

Investors with a lot of money to spend have taken a bearish stance on Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with OXY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Occidental Petroleum.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 46%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $549,965, and 2 are calls, for a total amount of $211,500.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $27.5 to $67.5 for Occidental Petroleum over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Occidental Petroleum's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Occidental Petroleum's whale activity within a strike price range from $27.5 to $67.5 in the last 30 days. 
<h3>Occidental Petroleum Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742222780_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.11</td>
<td>$1.1</td>
<td>$1.11</td>
<td>$42.50</td>
<td>$142.8K</td>
<td>5.6K</td>
<td>1.3K</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$21.45</td>
<td>$21.0</td>
<td>$21.3</td>
<td>$27.50</td>
<td>$106.5K</td>
<td>106</td>
<td>50</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$21.3</td>
<td>$20.95</td>
<td>$21.0</td>
<td>$27.50</td>
<td>$105.0K</td>
<td>106</td>
<td>100</td>
</tr>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.11</td>
<td>$1.07</td>
<td>$1.11</td>
<td>$42.50</td>
<td>$88.8K</td>
<td>5.6K</td>
<td>2.1K</td>
</tr>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$20.5</td>
<td>$20.35</td>
<td>$20.43</td>
<td>$67.50</td>
<td>$42.9K</td>
<td>1.0K</td>
<td>123</td>
</tr>
</tbody>
</table>

<h3>About Occidental Petroleum</h3>
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1,327 thousand barrels of oil equivalent per day in 2024 at a ratio of roughly 50% oil and natural gas liquids and 50% natural gas.
<h3>Occidental Petroleum's Current Market Status</h3>
<ul>
<li>With a volume of 1,683,355, the price of OXY is down -0.06% at $46.5. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 50 days.</li>
</ul>
<h3>What Analysts Are Saying About Occidental Petroleum</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $58.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Occidental Petroleum, maintaining a target price of $50. 
&#x2A; In a cautious move, an analyst from Raymond James downgraded its rating to Outperform, setting a price target of $64. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Occidental Petroleum, targeting a price of $56. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on Occidental Petroleum with a target price of $52. 
&#x2A; In a cautious move, an analyst from Stephens &amp; Co. downgraded its rating to Overweight, setting a price target of $71. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Occidental Petroleum options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

Spotlight on Occidental Petroleum: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with JD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 18 uncommon options trades for JD.com.
This isn't normal.
The overall sentiment of these big-money traders is split between 38% bullish and 50%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $165,150, and 13 are calls, for a total amount of $640,175.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $37.5 and $48.0 for JD.com, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for JD.com options trades today is 8770.8 with a total volume of 13,293.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for JD.com's big money trades within a strike price range of $37.5 to $48.0 over the last 30 days.
<h3>JD.com 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742222774_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$1.94</td>
<td>$1.87</td>
<td>$1.94</td>
<td>$45.00</td>
<td>$97.0K</td>
<td>15.2K</td>
<td>507</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.92</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$45.00</td>
<td>$87.1K</td>
<td>17.5K</td>
<td>3.0K</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$7.9</td>
<td>$7.8</td>
<td>$7.81</td>
<td>$37.50</td>
<td>$78.1K</td>
<td>6.0K</td>
<td>100</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.45</td>
<td>$41.00</td>
<td>$69.0K</td>
<td>17.1K</td>
<td>221</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$48.00</td>
<td>$55.0K</td>
<td>395</td>
<td>200</td>
</tr>
</tbody>
</table>

<h3>About JD.com</h3>
JD.com is the third-largest Chinese e-commerce platform by GMV in 2024. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
<h3>Where Is JD.com Standing Right Now?</h3>
<ul>
<li>With a volume of 3,770,016, the price of JD is up 2.43% at $44.21. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 59 days.</li>
</ul>
<h3>Professional Analyst Ratings for JD.com</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $52.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on JD.com, which currently sits at a price target of $58. 
&#x2A; An analyst from Susquehanna persists with their Neutral rating on JD.com, maintaining a target price of $45. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on JD.com with a target price of $55. 
&#x2A; An analyst from Barclays persists with their Overweight rating on JD.com, maintaining a target price of $55. 
&#x2A; An analyst from Mizuho persists with their Outperform rating on JD.com, maintaining a target price of $50. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest JD.com options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Smart Money Is Betting Big In JD.com Options

Investors with a lot of money to spend have taken a bullish stance on Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ORCL, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Oracle.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 33%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $79,500, and 13 are calls, for a total amount of $1,394,354.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $115.0 to $175.0 for Oracle over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Oracle's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Oracle's whale trades within a strike price range from $115.0 to $175.0 in the last 30 days. 
<h3>Oracle 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742222769_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$0.96</td>
<td>$0.77</td>
<td>$0.9</td>
<td>$175.00</td>
<td>$270.0K</td>
<td>1.9K</td>
<td>3.0K</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$22.4</td>
<td>$22.15</td>
<td>$22.15</td>
<td>$140.00</td>
<td>$221.5K</td>
<td>62</td>
<td>0</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$21.65</td>
<td>$20.85</td>
<td>$21.39</td>
<td>$140.00</td>
<td>$213.7K</td>
<td>557</td>
<td>201</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$21.85</td>
<td>$20.6</td>
<td>$21.24</td>
<td>$140.00</td>
<td>$212.4K</td>
<td>557</td>
<td>100</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$11.9</td>
<td>$11.65</td>
<td>$11.79</td>
<td>$150.00</td>
<td>$117.9K</td>
<td>1.6K</td>
<td>145</td>
</tr>
</tbody>
</table>

<h3>About Oracle</h3>
Oracle provides enterprise applications and infrastructure offerings around the world through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used for running online transaction processing and data warehousing workloads. Besides database systems, Oracle also sells enterprise resource planning, or ERP, customer relationship management, or CRM, and human capital management, or HCM, applications. Today, Oracle has more than 159,000 full-time employees in over 170 countries.
In light of the recent options history for Oracle, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Oracle Standing Right Now?</h3>
<ul>
<li>With a volume of 2,487,458, the price of ORCL is up 2.37% at $152.81. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 85 days.</li>
</ul>
<h3>What Analysts Are Saying About Oracle</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $170.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on Oracle with a target price of $135. 
&#x2A; An analyst from Guggenheim downgraded its action to Buy with a price target of $220. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Oracle with a target price of $170. 
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Overweight rating on Oracle with a target price of $175. 
&#x2A; Maintaining their stance, an analyst from DA Davidson continues to hold a Neutral rating for Oracle, targeting a price of $150. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Oracle with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

ORCL

Decoding Oracle's Options Activity: What's the Big Picture?

Noland Arbaugh, a 30-year-old quadriplegic man from Yuma, Arizona, has become the first <a href="https://www.benzinga.com/news/24/05/38873201/elon-musks-neuralink-patient-noland-arbaugh-shares-his-journey-from-paralysis-to-cyborg-once-you-get">human recipient of Elon Musk&#8217;s Neuralink brain implant</a>—a device that now allows him to control computers using only his thoughts.
&#8220;Sometimes I forget how impressive it is, because it&#8217;s so natural to me,&#8221; Arbaugh <a href="https://www.theguardian.com/science/2025/feb/08/elon-musk-chip-paralysed-man-noland-arbaugh-chip-brain-neuralink">told The Guardian</a> as he demonstrated playing chess, browsing the internet, and playing video games with swift cursor movements while his hands remained motionless on his wheelchair.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
Arbaugh was paralyzed in June 2016 after a swimming accident at age 22. For nearly eight years, he relied entirely on family members for basic needs and could only use computers through a mouth-controlled stick with conductive fabric, which he found frustrating and limiting.
In January 2024, just four months after applying to Neuralink&#8217;s first human trial, Arbaugh underwent surgery to have the coin-sized N1 chip implanted in his brain. According to The Guardian, the device contains 1,024 electrodes distributed across 64 ultra-thin threads inserted into his motor cortex by a specialized robot.
The technology works by reading electrical signals produced by neurons—which still fire in paralyzed individuals but can&#8217;t transmit down damaged spinal cords—and converting them into computer commands. Initially, Arbaugh controlled the cursor by attempting to move his hand, but within two weeks, he could direct it through purely &#8220;imagined&#8221; movements.
&#8220;You&#8217;re not thinking about doing it—you&#8217;re just willing the cursor to go wherever you want,&#8221; he explained to The Guardian. &#8220;When I first moved it with imagined movement, it blew my mind.&#8221;
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
The journey hasn&#8217;t been without setbacks. A month after surgery, Arbaugh began losing cursor control when engineers discovered 85% of the implant&#8217;s threads had retracted because his brain&#8217;s natural pulsing movement hadn&#8217;t been properly accounted for. Rather than performing another surgery, Neuralink adjusted the software to read groups of neuron signals instead of individual cells.
While Arbaugh has achieved typing speeds of nearly 25 words per minute, he acknowledges limitations of the first-generation technology. Two more participants have since received improved versions of the implant, according to The Guardian.
Musk&#8217;s ambitions extend far beyond current capabilities. The Guardian reported that he ultimately envisions the technology writing information back to the brain—potentially allowing users to experience new senses, restore vision to the blind, or bypass severed spinal cords entirely.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Arbaugh, who calls his implant &#8220;Eve,&#8221; recognizes potential ethical concerns, including privacy issues and the theoretical possibility of mind or body control. &#8220;At this point, it&#8217;s only reading my signals, but it will be able to write at some point, and sending signals into the brain can be scary,&#8221; he told The Guardian.
For now, Arbaugh dreams of connecting to a Tesla car or humanoid robot to gain independence. When the six-year study concludes, Neuralink will either remove his implant or switch it off—with no promises of an upgrade.
&#8220;I&#8217;m content with my lot in life,&#8221; Arbaugh said. &#8220;I was before Neuralink, and I will be again after. I&#8217;ll find a way.&#8221;
Read Next:
<ul>
<li>This Startup Is On The Brink Of A Huge Disruption To The $654 Billion Industry – <a href="https://www.benzinga.com/money/venhub-adv">Invest In It Before It Fulfills 800 Pre-Orders</a></li>
<li>Hasbro, MGM Resorts, and Sketchers Use this Pre-IO AI Marketing Firm — <a href="https://www.benzinga.com/money/rad-intel">and You Can Own a Piece of it From $0.55/Share</a></li>
</ul>

Paralyzed Man Moves Objects With His Mind—Thanks To Elon Musk's Brain Chip

Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) has outperformed the market over the past 15 years by 10.08% on an annualized basis producing an average annual return of 21.12%. Currently, Lululemon Athletica has a market capitalization of $39.07 billion. 
Buying $100 In LULU: If an investor had bought $100 of LULU stock 15 years ago, it would be worth $1,830.96 today based on a price of $320.79 for LULU at the time of writing.
<h3>Lululemon Athletica's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742222714_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LULU

Here's How Much You Would Have Made Owning Lululemon Athletica Stock In The Last 15 Years

On Monday, Zoom Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) disclosed the new agentic AI Companion capabilities, expanded AI Companion skills and<a href="https://www.benzinga.com/pressreleases/25/03/g44355391/zoom-debuts-new-agentic-ai-skills-and-agents-for-zoom-ai-companion" target="_blank" rel="noreferrer noopener"> AI enhancements across its platform</a>.
These updates span Zoom Meetings, Team Chat, Docs, Phone, Whiteboard, Contact Center, industry solutions and more.
Zoom also introduced Zoom Drive, a centralized hub for storing meeting and productivity assets, including Zoom Docs, to streamline access across Zoom Workplace. The feature is set to launch in May.
Zoom AI Companion remains available at no extra cost for customers with paid Zoom user accounts.
The company added that advanced AI Companion features, custom agent setups and third-party agent integrations may come with additional fees or separate pricing.
Zoom is enhancing its AI Companion with advanced skills and agents to boost productivity, with new features including calendar management, clip generation and writing assistance.
Also, Zoom's open platform will soon support third-party and custom agents for tasks like sales RFPs and IT service requests, with AI Companion orchestrating the execution.
Zoom&#8217;s Custom AI Companion add-on allows organizations to tailor the AI Companion to their specific needs using AI Studio.
Businesses can create custom meeting templates, dictionaries and integrate their own data, including third-party apps.
The add-on includes a personal AI coach, custom meeting summary templates, and Custom Avatars for video clips and will be available for purchase in April for $12 per user per month, with the personal coach launching in June.
Steven Carroll, chief information officer at Saint Leo University said, &#8220;This technology isn&#8217;t just about efficiency; it allows our employees to spend less time on manual tasks and more time on meaningful collaboration, and focus on what matters most: supporting our students&#8217; educational journey.&#8221;
Investors can gain exposure to the stock via&nbsp;Global X Cloud Computing ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOU#NASDAQ">CLOU</a>) and StockSnips AI-Powered Sentiment US All Cap ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWZ#NASDAQ">NEWZ</a>).
Price Action: ZM shares are up 0.67% at $74.70 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43953722/zoom-eyes-ai-powered-growth-analyst-highlights-innovation-momentum-revenue-challenges" target="_blank" rel="noreferrer noopener">Zoom Eyes AI-Powered Growth, Analyst Highlights Innovation Momentum, Revenue Challenges</a></li>
</ul>
Photo: Shutterstock

CLOU

NEWZ

Zoom Introduces Customizable AI Companion With New Add-Ons For Businesses

Macro Economic Events

Market Summary

Economics

TSLA

Benzinga Market Summary: S&P Rebound Continues Despite Mixed Retail Sales Data, Mizuho Cuts Tesla PT, Intel Rises On Reports CEO Lip-Bu Tan Plans Overhaul Of chip Manufacturing

Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) is preparing to introduce new <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence-powered solutions</a>.
What Happened: The company is rolling out updates. The goal is to improve workflows in AI Assistant for Webex Suite and simplify employee interactions with Webex Calling Customer Assist and AirPlay on Cisco Devices for Microsoft Teams Rooms.
With updates to the Cisco AI Assistant for Webex Contact Center and the availability of Webex AI Agent, Cisco is transforming contact centers into customer experience hubs.
New solutions for end users and IT teams include Webex Calling Customer Assist, enhanced features in Webex Control Hub, and new workflow automation capabilities for the Cisco AI Assistant for Webex.
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44357674/restaurant-sales-sink-recession-warning-or-just-weather-driven-dip">Restaurant Sales Sink: Recession Warning Or Just Weather-Driven Dip?</a>
Why It Matters: The Cisco AI Assistant for Webex Contact Center, with new features like suggested responses and real-time transcription arriving in the second quarter of 2025, enhances both agent efficiency and customer experience.
The product enhances efficiency by integrating with enterprise apps like Salesforce, ServiceNow, and Jira, enabling users to complete tasks faster and automatically share meeting summaries.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Telecommunications ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYZ#BATS">IYZ</a>) and&nbsp;First Trust NASDAQ Cybersecurity ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIBR#NASDAQ">CIBR</a>).
Price Action: Cisco shares are up 1.39% at $60.66 premarket at the last check Monday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44353699/niu-q4-rides-high-on-demand-for-e-scooters-but-gross-margins-decline-amid-higher-costs" target="_blank" rel="noreferrer noopener">Niu Q4 Rides High On Demand For E-Scooters, But Gross Margins Decline Amid Higher Costs</a></li>
</ul>
Image: Shutterstock

Contracts

CIBR

CSCO

iShares Dow Jones US Telecommunications Sector Index Fund

Cisco Unveils AI-Powered Solutions With Webex AI Agent

INTC

Intel shares are trading higher after Reuters reported new CEO Lip-Bu Tan plans to overhaul chip design and manufacturing, restart AI efforts, and examine further cost cuts.

NanoVibronix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares are trading higher by 37.4% to $3.03 during Monday&#8217;s session after the company announced Friday that it published its UroShield study, which <a href="https://www.benzinga.com/pressreleases/25/03/b44325968/successful-independent-study-of-the-nanovibronix-uroshield-device-published-in-the-australian-and-">showed positive data</a>, including an 86% UTI reduction.
What To Know: NanoVibronix announced that a study on its UroShield device, published in The Australian and New Zealand Continence Journal, confirms its effectiveness in preventing catheter-associated urinary tract infections. 
The study found that UroShield reduced UTIs by 86%, catheter blockages by 70%, and bladder irrigations by 82.8%, while also improving patient comfort and reducing catheter changes. Clinicians reported lower intervention needs and nursing time, leading to measurable cost savings. 
What Else: A Quality Improvement project in New Zealand demonstrated a 63.5% reduction in resource costs over five months, highlighting UroShield's potential to enhance patient care and reduce healthcare expenses. 
CEO Brian Murphy emphasized its role in improving quality of life and easing nursing workloads, reinforcing its suitability for broader adoption in healthcare settings.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44355195/retail-sales-rebound-less-than-expected-in-february-online-healthcare-spending-show-strong-gains">Retail Sales Rebound Less Than Expected In February: Online, Healthcare Spending Show Strong Gains</a>
<h2 class="wp-block-heading">How To Buy NAOV Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in NanoVibronix&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NAOV has a 52-week high of $13.97 and a 52-week low of $1.02.

NAOV

NanoVibronix (NAOV) Stock Is Skyrocketing: What's Going On?

American Eagle Outfitters Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) shares are trading higher Monday after the company announced a $200 million <a href="https://www.benzinga.com/pressreleases/25/03/b44354677/aeo-inc-announces-200-million-accelerated-share-repurchase-program">accelerated share repurchase program</a>.
What Happened: American Eagle entered into an accelerated share repurchase agreement with Bank of America to repurchase $200 million of its common stock.
The company expects to complete the accelerated share repurchase agreement in connection with its existing buyback authorization of 68.5 million shares. The accelerated buyback equates to approximately 18.1 million shares at Friday&#8217;s closing price.
&#8220;We are pleased to announce an accelerated share repurchase program, which reflects our strong capital position and confidence in our long-term strategic growth plan. This program, combined with our quarterly cash dividend, underscores our commitment to a balanced approach to capital allocation and delivering strong returns to shareholders,&#8221; said Jay Schottenstein, executive chairman and CEO of American Eagle.
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44355195/retail-sales-rebound-less-than-expected-in-february-online-healthcare-spending-show-strong-gains">Retail Sales Rebound Less Than Expected In February: Online, Healthcare Spending Show Strong Gains</a>
<h3 class="wp-block-heading">Is AEO A Good Stock To Buy?</h3>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/AEO">American Eagle</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. American Eagle does pay a dividend, which yields 2.98% per year as of the closing price on Mar. 17, 2025. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/AEO">American Eagle</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
AEO Price Action: <a href="http://benzinga.com/quote/aeo">American Eagle shares</a> were up 6.37% at $11.77 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Buybacks

Why American Eagle Stock Is Rising Monday

Wells Fargo analyst Matthew Akers maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Underweight and raises the price target from $103 to $113.

Wells Fargo Maintains Underweight on Boeing, Raises Price Target to $113

Susquehanna analyst Charles Minervino maintains MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) with a Positive and lowers the price target from $17 to $15.

Susquehanna Maintains Positive on MRC Global, Lowers Price Target to $15

Health Care

Press Releases

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

IO Biotech Announces Participation in Upcoming Investor Conferences

Earnings

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Financing

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Comments

IO Biotech

Noticias

Últimas noticias sobre IO Biotech (NASDAQ:IOBT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL